Antibody-Drug Conjugate Field Expanding in Oncology
OncLive
Clinical Research
,
Drug
,
Genetics
,
Immune Therapy
,
Trials
,
News
,
Drug Development
Monoclonal antibodies that have the ability to selectively target cancer cells by binding to specific tumor-associated antigens have carved out an important role in anticancer therapy.
Related Articles
- A Phase I Study of Humanized 3F8 plus Interleukin-2 in Patients with High-Risk Neuroblastoma and GD2-Positive Tumors also categorized in Clinical Research
- A Phase I Study of LDK378 in Children with Cancers Containing an ALK Mutation also categorized in Clinical Research
- A Phase I Study of Panitumumab in Children with Solid Tumors also categorized in Clinical Research
- Experimental antibody temporarily halts progression of neuroblastoma in children also categorized in Clinical Research
- A Phase I Study of the Hu3F8 Antibody plus GM-CSF in Patients with Relapsed/Refractory Neuroblastoma also categorized in Clinical Research
- A Phase I Study of Humanized 3F8 Monoclonal Antibody in Patients with High-Risk Neuroblastoma and GD2-Positive Tumors also categorized in Clinical Research
- A Phase I Study of Intrathecal Radioimmunotherapy Using 131I-8H9 for Central Nervous System/Leptomeningeal Cancers also categorized in Clinical Research
- A Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors also categorized in Clinical Research
- Endowment Gift Establishes Haworth Family Pediatric Oncology Innovative Therapeutics Clinic at Helen DeVos Children’s Hospital also categorized in Clinical Research
- A Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma also categorized in Clinical Research